The company raised its quarterly dividend by 6.8% in January 2026, marking 52 consecutive years of dividend growth, solidifying its status as a Dividend King. The dividend increase is supported by strong cash flow coverage. A financial analysis slightly raised the firm's implied fair value estimate due to a marginally lower discount rate, reflecting a generally constructive view on its execution, particularly in medical devices. Institutional investors hold a significant 80% stake in the company.